The Ministry of Commerce holds a roundtable meeting for foreign pharmaceutical companies in the industry.

On May 22nd, Vice Minister of Commerce and Deputy Representative for International Trade Negotiations, Ling Ji, chaired a roundtable meeting for foreign pharmaceutical companies. Representatives from more than 50 foreign companies such as Sanofi, Novartis, Merck, Abbott Medical, Gilead Sciences, Lilly, and Danaher attended the meeting. Relevant departments from the Ministry of Commerce, the Ministry of Industry and Information Technology, the National Health Commission, the National Medical Security Administration, and the National Medical Products Administration also participated and exchanged views with the companies on-site. Ling Ji stated that the 13th Five-Year Plan period is a critical time for promoting the construction of a Healthy China, with China's pharmaceutical industry having a comprehensive innovation ecosystem and the world's largest medical and health service system, creating huge opportunities for multinational pharmaceutical companies to develop in China in the long term. The Chinese government adheres to a people-centered approach, continuously improves the quality of medical products and services, enhances price formation mechanisms and regulatory systems, expands openness in related fields, and legally ensures national treatment for foreign enterprises. All countries are welcomed to continue deepening their presence in the Chinese market and share in China's development dividends. The foreign companies attending the meeting welcomed the series of regulations and policies recently issued by relevant national departments in the pharmaceutical field, and expressed their willingness to further expand their investments in China to support the construction of a "Healthy China".
Latest news
5 h ago
  • 1
  • 2
  • 3
  • 4
  • 5
  • 777